January 13, 2014 10:27 AM | 1 min read
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
In a report published Monday, Credit Suisse analyst Hamzah Mazari initiated coverage on Stericycle, Inc. (NASDAQ: SRCL) at Outperform, establishing a $140.00 price target. According to the report, the $140.00 price target is based on the analyst's normalized EBIDTA estimate of ~$920mm at ~16.5x multiple discounted back.“Barrier to entry in the medical waste business is not just having a disposal network advantage but also high route density similar to the municipal solid waste business,” the report noted. “We believe having captive US market share in a stable business (over 95% of revenues are under long term contracts with automatic renewal clauses) with significant global and domestic secular drivers insulates Stericycle from economic cycles.”Some highlights from the report included: -Mix and Cross Selling is Underappreciated. -International Markets Remain Upside.SRCL closed Friday at 115.42.
27% profits every 20 days?
This is what Nic Chahine averages with his options buys. Not selling covered calls or spreads... BUYING options. Most traders don't even have a winning percentage of 27% buying options. He has an 83% win rate. Here's how he does it.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.